Sysmex India

The success of a medical laboratory setup is driven by the innovative solutions provided to the patients as well as to the clinical community. The data and inferences generated in medical laboratories are the keys to drive the series of clinical decisions. Being the most trusted partner for hematology solutions, Sysmex has designed and developed a series of most advanced hematology analyzers of the modern era. The medical laboratories deploying Sysmex hematology solutions have been recognized as the referral laboratories. The overwhelming global response for the Sysmex XN series led to the introduction of compact yet clinically advanced XN-L series of analyzers. XN-L series shares the same technology platform as that of XN series and hence the same clinical and operational values are added to the labs having mid to lower volumes.

XN-L series is available in three variants with different aspiration modes, level of automation and options for future upgradability. TheXN-L series provides 5-part differential count of WBCs with reportable automated count of immature granulocytes, a prognostic marker of sepsis. IG counts are used to discriminate between sepsis and non-infectious inflammatory conditions, particularly it can be life saving for ICU patients. IG is further being evaluated as a biomarker for myelodysplastic syndromes and myocardial infarctions.

CBC is a primary tool for investigation of fever and infections; XN-L series is equipped to flag (pRBC flag) the presence of mature parasitic stages (schizonts or gametocytes) of plasmodium, used to screen malarial blood samples effectively. pRBC flag also eliminates the chances of counting infected RBCs as WBCs hence auto correcting the WBC counting as well.

The XN-L series provides further advanced clinical values to the medical laboratories like indices of erythropoiesis (reticulocyte absolute counting and Hb content, immature reticulocyte fractions-IRF), indices of thrombopoiesis (immature platelet fraction-IPF), 2-part differential body fluid (BF) analysis for mono and poly nuclear cells to distinguish viral and bacterial infections, chemotherapy monitoring by L-WBC mode. Recently IRF and Ret-He have gained attention from hemato-oncologists and nephrologists; laboratories have started providing interpretations of reticulocyte and its indices as a new practice, which is helping the physicians to assess the various cases of anemia.

The important clinical indices obtained from the retic mode of XN-L are IRF and IPF. IRF is now considered as a better marker for bone-marrow regeneration than absolute neutrophil count (ANC). IPF is a USFDA-approved parameter (an improvement over mean platelet volume) and reliable even when PLT counts are low and helps for evaluating thrombocytopenia. Also, it is an effective risk-monitoring indicator during coronary artery disease (CAD) and is gaining popularity among cardiologists.

The precise classification and counting of various blood cells by XN-L series is obtained by the synergistic effect of patented Sysmex technologies, fluorescence flow-cytometry (FFCM), hydrodynamic focusing (HDF), electrical impedance, adaptive cluster-analysis system (ACAS) along with the highly specific reagents designed for different blood cells and their internal granules/organelles or nucleic acids.

Sysmex XN-L series offers state-of-the-art clinical, managerial and operational benefits and is accepted as the best hematology analyzer for mid-volume laboratories. Since the direct operations in India, there have been more than 200 orders for XN-L and XN series.